Skip to main content

“Our employees have coped excellently with the second pandemic year and all its challenges. Despite strained supply chains, we were able to support our customers in their demanding projects in the development and production of biopharmaceuticals and vaccines, grew strongly in both divisions, and achieved, and partly exceeded, our financial targets that were raised several times during the year. We have also made excellent progress in the expansion of our production capacities. I am especially pleased that we were able to create more than 3,000 additional jobs.

We are very optimistic about our future business development. Following the jump in profitability in 2021, we are aiming at achieving the same high level of profitability in the current fiscal year. We have also set ourselves an ambitious target to continuously reduce our CO2 emission intensity.”

Chairman’s Message

Sales revenue


in constant FX: +49.3%

Underlying EBITDA



Order intake


in constant FX: +52.3%




Market capitalization



Group Business Development and Divisions

Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with exceptionally strong growth and a jump in profitability. The company achieved significant double-digit percentage growth in order intake, sales revenue and earnings.

Group Business Development

Bioprocess Solutions

In the Bioprocess Solutions Division, Sartorius offers a broad product portfolio that covers all steps in the production of a biopharmaceutical. The company has held leading market positions for years in its core technologies, such as filtration, fermentation, cell cultivation and fluid management.

Business Development of Bioprocess Solutions

Lab Products & Services

The Lab Products & Services Division offers laboratories in the pharmaceutical and biopharmaceutical industries as well as at academic research institutes innovative solutions for bioanalytics, in addition to premium laboratory products, consumables and services. Sartorius is among the market leaders in laboratory balances, pipettes and lab consumables.

Business Development of Lab Products & Services


Sartorius expects dynamic development with double-digit growth in sales revenue and sustained high profitability in the current year as well. Based on the company’s strong performance in fiscal 2021, management also raised its mid-term forecast for profitability again.



Consolidated sales revenue is projected to increase by about 15% to 19%. Following the jump in profitability in 2021, the company expects its underlying EBITDA margin to reach a figure at the high prior-year level of about 34%.



Strategy and Long-Term Targets

The underlying EBITDA margin for the Group is now expected to be around 34% in 2025 (previously around 32%). The consolidated sales revenue target for 2025 had already been substantially raised at the beginning of 2021 and remains unchanged at around 5 billion euros.